Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Safety analysis of entrectinib for NTRK fusion tumours

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 693

Dr George D. Demetri - Harvard Cancer Center, Boston, USA

Dr Demetri speaks with ecancer at ESMO 2018 in Munich about the pooled efficacy and safety results from the STARTRK-1, STARTRK-2 and ALKA-372-001 of entrectinib in NTRK fusion tumours.

He outlines his professional experience in treating sarcomas, in which TRK fusions are rare compared to other tumour sites, and the high overall response from sarcoma patients in these trials.

Dr Demitri notes the activity of entrectinib in the central nervous system to control metastases, and considers the future development of drugs to combat treatment resistance.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation